報價延遲最少15分鐘:2024/09/27 23:06 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.26 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.57/1.22
|
|
企業價值
52.08B
|
| 資產負債 |
|
每股賬面淨值
5.31
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
15.44B
|
|
每股收益
8.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/09/27 23:06 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space,including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power. |